{"entity":{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","aka":["HUDSON"],"tldr":"A phase 2 trial of Durvalumab, Ceralasertib, Olaparib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy is a phase 2 interventional study registered as NCT03334617 by AstraZeneca, with 528 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-09-13. Interventions recorded: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03334617","url":"https://clinicaltrials.gov/study/NCT03334617"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","ceralasertib","olaparib","oleclumab","trastuzumab-deruxtecan"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03334617-nat-med-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03334617","phase":"2","setting":"An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).","sponsor":"AstraZeneca","started":"2017-12-18","startedType":"actual","yearReported":2025,"enrolled":528,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)","primary":true,"unit":"%","arms":[{"name":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":9.5,"note":"80% CI 2.6 to 23.4; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication"},{"name":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":4.8,"note":"80% CI 0.5 to 17.3"},{"name":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","n":22,"value":0,"note":"80% CI 0.0 to 9.9"},{"name":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","n":23,"value":4.3,"note":"80% CI 0.5 to 15.9"},{"name":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","n":23,"value":0,"note":"80% CI 0.0 to 9.5"},{"name":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","n":22,"value":0,"note":"80% CI 0.0 to 9.9"},{"name":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","n":31,"value":25.8,"note":"80% CI 15.7 to 38.5"},{"name":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","n":37,"value":8.1,"note":"80% CI 3.0 to 17.2"},{"name":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","n":58,"value":8.6,"note":"80% CI 4.3 to 15.4"},{"name":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","n":1,"note":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod…"},{"name":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","n":23,"value":4.3,"note":"80% CI 0.5 to 15.9"},{"name":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","n":9,"value":0,"note":"80% CI 0.0 to 22.6"},{"name":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","n":25,"value":4,"note":"80% CI 0.4 to 14.7"},{"name":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":23,"value":21.7,"note":"80% CI 11.0 to 36.6"},{"name":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":20,"value":35,"note":"80% CI 20.7 to 51.8"},{"name":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","n":22,"value":22.7,"note":"80% CI 11.5 to 38.1"},{"name":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","n":15,"value":0,"note":"80% CI 0.0 to 14.2"},{"name":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","n":18,"value":16.7,"note":"80% CI 6.3 to 33.4"},{"name":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","n":24,"value":8.3,"note":"80% CI 2.2 to 20.7"},{"name":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","n":34,"value":0,"note":"80% CI 0.0 to 6.5"},{"name":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","n":17,"value":11.8,"note":"80% CI 3.2 to 28.4"},{"name":"Module 11 Cohort C.11.240: AZD6738 240 mg","n":38,"value":2.6,"note":"80% CI 0.3 to 9.9"}],"source":"https://clinicaltrials.gov/study/NCT03334617?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":9.63,"note":"80% CI 5.26 to 15.97; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication"},{"name":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":5.75,"note":"80% CI 5.29 to 10.84"},{"name":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","n":22,"value":7.16,"note":"80% CI 4.93 to 10.28"},{"name":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","n":23,"value":15.51,"note":"80% CI 9.33 to 20.86"},{"name":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","n":23,"value":6.01,"note":"80% CI 3.55 to 6.51"},{"name":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","n":22,"value":11.2,"note":"80% CI 9.72 to 12.55"},{"name":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","n":31,"value":15.8,"note":"80% CI 14.16 to 22.80"},{"name":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","n":38,"value":10.22,"note":"80% CI 5.82 to 11.30"},{"name":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","n":58,"value":11.37,"note":"80% CI 9.13 to 15.80"},{"name":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","n":1,"note":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod…"},{"name":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","n":23,"value":10.97,"note":"80% CI 7.59 to 15.74"},{"name":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","n":9,"value":7.06,"note":"80% CI 4.90 to 11.99"},{"name":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","n":25,"value":12.78,"note":"80% CI 7.39 to 20.96"},{"name":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":23,"value":9.53,"note":"80% CI 6.57 to 12.42"},{"name":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":20,"value":10.61,"note":"80% CI 8.90 to 20.60"},{"name":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","n":22,"value":14.19,"note":"80% CI 11.86 to 19.88"},{"name":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","n":15,"value":14.23,"note":"80% CI 6.08 to 17.18"},{"name":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","n":19,"value":7.95,"note":"80% CI 5.59 to 8.64"},{"name":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","n":24,"value":12.91,"note":"80% CI 7.39 to 20.50"},{"name":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","n":34,"value":5.95,"note":"80% CI 4.01 to 10.05"},{"name":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","n":17,"value":7.03,"note":"80% CI 4.37 to 12.71"},{"name":"Module 11 Cohort C.11.240: AZD6738 240 mg","n":38,"value":6.6,"note":"80% CI 5.85 to 9.13"}],"source":"https://clinicaltrials.gov/study/NCT03334617?tab=results"},{"endpoint":"Progression-Free Survival (PFS) Per RECIST v1.1","unit":"months","arms":[{"name":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":2.79,"note":"80% CI 1.41 to 5.26; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication"},{"name":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","n":21,"value":1.41,"note":"80% CI 1.38 to 1.81"},{"name":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","n":22,"value":3.38,"note":"80% CI 2.10 to 4.93"},{"name":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","n":23,"value":4.17,"note":"80% CI 2.69 to 4.37"},{"name":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","n":23,"value":1.68,"note":"80% CI 1.64 to 2.99"},{"name":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","n":22,"value":3.09,"note":"80% CI 2.83 to 6.14"},{"name":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","n":31,"value":7.43,"note":"80% CI 5.59 to 9.43"},{"name":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","n":38,"value":2.96,"note":"80% CI 1.91 to 3.09"},{"name":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","n":58,"value":4.21,"note":"80% CI 3.02 to 4.96"},{"name":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","n":1,"note":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod…"},{"name":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","n":23,"value":1.61,"note":"80% CI 1.41 to 2.76"},{"name":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","n":9,"value":1.41,"note":"80% CI 1.35 to 1.81"},{"name":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","n":25,"value":2.69,"note":"80% CI 1.74 to 4.17"},{"name":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":23,"value":2.83,"note":"80% CI 2.33 to 5.45"},{"name":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","n":20,"value":5.52,"note":"80% CI 5.32 to 5.72"},{"name":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","n":22,"value":4.17,"note":"80% CI 2.56 to 9.36"},{"name":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","n":15,"value":3.42,"note":"80% CI 2.14 to 7.62"},{"name":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","n":19,"value":1.48,"note":"80% CI 1.41 to 2.23"},{"name":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","n":24,"value":3.68,"note":"80% CI 2.83 to 7.33"},{"name":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","n":34,"value":1.68,"note":"80% CI 1.61 to 2.56"},{"name":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","n":17,"value":2,"note":"80% CI 1.71 to 2.79"},{"name":"Module 11 Cohort C.11.240: AZD6738 240 mg","n":38,"value":2.86,"note":"80% CI 2.73 to 3.02"}],"source":"https://clinicaltrials.gov/study/NCT03334617?tab=results"}]},"route":"/trials/nct03334617/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ceralasertib","kind":"drug","name":"Ceralasertib","route":"/drugs/ceralasertib/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/"}]}}